Literature DB >> 9331144

Clinical application of gastric histology to monitor treatment of dual therapy in H. pylori eradication.

H B Yang1, B S Sheu, I J Su, C H Chien, X Z Lin.   

Abstract

This preliminary study attempted to test whether pretreatment gastric histology of H. pylori infection may affect the success of dual therapy and to identify which parameter of gastric histology could be improved after dual therapy. One hundred forty-five dyspeptic patients with H. pylori infection received a two-week course of dual therapy (Amoxicillin 500 mg every 6 hr plus omeprazole 20 mg twice a day). In each patient, three pairs of gastric biopsies, sampled from the antrum, lower body, and upper body near the cardia, were collected before treatment and four weeks after completion of dual therapy. The density of H. pylori (score 1-5) and parameters of the modified Sydney system were applied to test the severity of H. pylori-related gastric histology in each specimen. The total bacterial load (score 1-15) was a sum of the density of H. pylori sampled from three biopsies. The overall rate of H. pylori eradication rate by dual therapy is 73.1% (106/145). Univariate analysis of parameters in pretreatment histology disclosed that the presence of mucosal atrophy (P < 0.01), lymphoid follicles (P < 0.005), and higher-density H. pylori (P < 0.001) predisposed to dual therapy failure. Multivariate analysis by stepwise logistic regression further confirmed that both the density of bacteria and the presence of lymphoid follicles are the two major factors related to the outcome of dual therapy (P < 0.001). Four weeks after dual therapy was completed, only patients with successful eradication significantly improved in these gastric histology parameters: acute activity, chronic inflammation, eosinophil infiltration, and mucosal atrophy. However, the lymphoid follicle and intestinal metaplasia were not significantly improved during the study period. The eradication rates among three subgroups with different total bacterial loads (group I: 1-5; II: 6-10; III: 11-15) disclosed a downward trend (I: 89.1%; II: 73%; III: 52.7%). It is concluded that dual therapy could improve gastric histology especially among patients with successful eradication of H. pylori. Evaluating pretreatment histologic parameters, including the density of H. pylori and the presence of lymphoid follicles, is valuable in predicting the success of dual therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9331144     DOI: 10.1023/a:1018894606541

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  In vitro selection of resistant Helicobacter pylori.

Authors:  C E Haas; D E Nix; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

2.  Helicobacter pylori and gastric cancer.

Authors:  R P Logan
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

3.  Increased density of Helicobacter pylori on antral biopsy is associated with severity of acute and chronic inflammation and likelihood of duodenal ulceration.

Authors:  K Alam; T T Schubert; S D Bologna; C K Ma
Journal:  Am J Gastroenterol       Date:  1992-04       Impact factor: 10.864

4.  Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.

Authors:  K Jaskiewicz; J A Louw; I N Marks
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

5.  Prevalence of lymphoid follicles and aggregates in Helicobacter pylori gastritis in antral and body mucosa.

Authors:  S Eidt; M Stolte
Journal:  J Clin Pathol       Date:  1993-09       Impact factor: 3.411

6.  Quantitative assessment of histological changes in chronic gastritis after eradication of Helicobacter pylori.

Authors:  A Di Napoli; R Petrino; M Boero; D Bellis; L Chiandussi
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

7.  Changes in the gastric mucosa following eradication of Helicobacter pylori.

Authors:  R M Genta; G M Lew; D Y Graham
Journal:  Mod Pathol       Date:  1993-05       Impact factor: 7.842

8.  Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study.

Authors:  J Valle; K Seppälä; P Sipponen; T Kosunen
Journal:  Scand J Gastroenterol       Date:  1991-10       Impact factor: 2.423

9.  Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori.

Authors:  E M Witteman; M Mravunac; M J Becx; W P Hopman; J S Verschoor; G N Tytgat; R W de Koning
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

Review 10.  Campylobacter pylori and peptic ulcer disease.

Authors:  D Y Graham
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

View more
  8 in total

Review 1.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

2.  Selection of lower cutoff point of [13C]urea breath test is helpful to monitor H. pylori eradication after proton pump inhibitor-based triple therapy.

Authors:  B S Sheu; S C Lee; H B Yang; A W Kuo; Y L Wang; S C Shiesh; J J Wu; X Z Lin
Journal:  Dig Dis Sci       Date:  2000-07       Impact factor: 3.199

3.  Increased numbers of Foxp3-positive regulatory T cells in gastritis, peptic ulcer and gastric adenocarcinoma.

Authors:  Hsin-Hung Cheng; Guan-Ying Tseng; Hsiao-Bai Yang; Hung-Jung Wang; Hwai-Jeng Lin; Wen-Ching Wang
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

4.  Serologic response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan.

Authors:  S C Shiesh; B S Sheu; H B Yang; H J Tsao; X Z Lin
Journal:  Dig Dis Sci       Date:  2000-04       Impact factor: 3.199

5.  Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with nonulcer dyspepsia.

Authors:  B S Sheu; H B Yang; Y L Wang; C H Chuang; A H Huang; J J Wu
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

6.  Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.

Authors:  Yuksel Gumurdulu; Ender Serin; Birol Ozer; Fazilet Kayaselcuk; Kursat Ozsahin; Arif Mansur Cosar; Murat Gursoy; Gurden Gur; Ugur Yilmaz; Sedat Boyacioglu
Journal:  World J Gastroenterol       Date:  2004-03-01       Impact factor: 5.742

7.  Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection.

Authors:  B-S Sheu; S-M Sheu; H-B Yang; A-H Huang; J-J Wu
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

8.  Eosinophil infiltration, gastric juice and serum eosinophil cationic protein levels in Helicobacter pylori-associated chronic gastritis and gastric ulcer.

Authors:  Selim A Aydemir; Isak Ozel Tekin; Gamze Numanoglu; Ali Borazan; Yucel Ustundag
Journal:  Mediators Inflamm       Date:  2004-12       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.